Evidence map›Paper›PMID 31266627›Full record

ReviewClinics in liver disease2019

HBV/HDV Coinfection: A Challenge for Therapeutics.

Christopher Koh, Ben L Da, Jeffrey S Glenn

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in liver disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  2. Observational
  3. Review
  4. Article
  5. Review
  6. HERACLIS_BLV_D: Increasing Response Rates During 2-Year Bulevirtide Real-Life Therapy in Chronic Hepatitis D.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Current perspectives of viral hepatitis.World journal of gastroenterology · 2024
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Christopher KohLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9B-16, MSC 1800, Bethesda, MD 20892, USA. Electronic address: christopher.koh@nih.gov.
Ben L DaDigestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, CRC, Room 4-5722, Bethesda, MD 20892, USA.
Jeffrey S GlennDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115A, 269 Campus Drive, Stanford, CA 94305, USA; Department of Medicine Microbiology & Immunology, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Rm. 3115A, 269 Campus Drive, Stanford, CA 94305, USA.
National Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USStanford University · US

Funding

Management and Treatment of Chronic Delta Hepatitis Infection and other Liver DiseasesZIADK075150 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOH, CHRISTOPHER · 2019 to 2025
$2.8M
Intramural NIH HHS Z99 DK999999
6 · The paper itself

Abstract

Chronic hepatitis D (CHD) results from an infection with the hepatitis B virus and hepatitis D virus (HDV). CHD is the most severe form of human viral hepatitis. Current treatment options consist of interferon alfa, which is effective only in a minority of patients. Study of HDV molecular virology has resulted in new approaches entering clinical trials, with phase-3 studies the most advanced. These include the entry inhibitor bulevirtide, the nucleic acid polymer REP 2139-Ca, the farnesyltransferase inhibitor lonafarnib, and pegylated interferon lambda. This article summarizes the available data on these emerging therapeutics.

Indexed as

Antiviral AgentsClinical Trials, Phase III as TopicCoinfectionDibenzocycloheptenesDrugs, InvestigationalFemaleHepatitis B, ChronicHepatitis B virusHepatitis D, ChronicHepatitis Delta VirusHumansInterferon-alphaMalePiperidinesPolyethylene GlycolsPrognosisAntiviral AgentsDibenzocycloheptenesDrugs, InvestigationalInterferon-alphalonafarnibpeginterferon alfa-2aPiperidinesPolyethylene GlycolsPyridinesRecombinant ProteinsCirrhosisClinical trialsHepatitis BHepatitis DTherapeutics

Identifiers

PMID31266627
PMCPMC6659751
OpenAlexW2945636357

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.